Loading
institutionsInstitution
Edinburgh Cancer Centre / CRUK Scotland Centre
Edinburgh's cancer centre at the Western General, backed by the university's Institute of Genetics and Cancer and known for breast, colorectal genetics and brain tumour research.
Also called: Western General HospitalInstitute of Genetics and CancerNHS Lothian cancer services
Overview
The Edinburgh Cancer Centre at the Western General Hospital serves south-east Scotland with medical and clinical oncology, and sits beside the University of Edinburgh's Institute of Genetics and Cancer, which incorporates the MRC Human Genetics Unit and the CRUK Scotland Centre shared with Glasgow. David Cameron chairs the Breast International Group and leads breast cancer trials from Edinburgh, Malcolm Dunlop's group identified inherited risk variants for colorectal cancer in Scottish populations, and Steven Pollard's laboratory studies glioblastoma stem cells. The Edinburgh Breast Unit is a UK reference for oncoplastic surgery and endocrine therapy studies. The centre is a hub for cancer informatics and the Scottish population health data used in screening research.
Location
Edinburgh, GB
Type
hospital · University of Edinburgh
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#177 · 30 points (0 Newsweek + 0 NCI + 30 from 15 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Western General Hospital, including child institutions. 134 works · 751 citations · 77% open access · 10% clinical trials · 4% reviews.
Oncology works per year
292022
222023
382024
282025
172026
Most works
- Peter S Hall15 works
- Mark D. Stares14 works
- Malcolm G. Dunlop10 works
- Sally Clive10 works
- Colin Barrie8 works
- David Cameron7 works
- Shahida Din7 works
- Stuart H. Ralston7 works
- Farhat V N Din7 works
- Melanie Mackean7 works
Most cited
- Breast cancer trials (BIG)
- Colorectal cancer genetics
- Glioblastoma biology
- CRUK Scotland Centre
- Cancer informatics
Charlie Gourley
Clinical Director, CRUK Scotland Centre
Ovarian cancerMedical oncologyGynaecological cancer genomics
Edinburgh medical oncologist and ovarian cancer researcher who is Clinical Director of the CRUK Scotland Centre.
David Cameron
Professor of Oncology, University of Edinburgh; Chair, Breast International Group
Breast cancerAdjuvant trialsTrial governance
David Cameron is a breast oncologist who chairs the Breast International Group.
Similar pages
- InstitutionComprehensive Cancer Center Vienna, Medical University of Vienna / AKH
Shares Breast International Group (BIG), CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Glioma & glioblastoma.
- CompanyAustrian Breast & Colorectal Cancer Study Group
Shares Breast International Group (BIG), CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- PersonOwen Sansom
Shares Beatson West of Scotland Cancer Centre / CRUK Scotland Institute, Cancer Research UK, Colorectal cancer.
- TreatmentMia (Mammography Intelligent Assessment)
Shares ANCHOR Centre, Aberdeen Royal Infirmary, HR-positive / HER2-negative breast cancer.
- IdeaOncology teams order germline tests; tele-genetic counsellors handle the results
Shares Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- CompanyGEICAM Spanish Breast Cancer Group
Shares Breast International Group (BIG), CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TrialA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Shares CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TrialA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Shares CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.